Program:
P53 plays a key role in the elimination of cells in which genetic damage has occurred, and thus it serves as a tumor suppressor gene. In about half of all cancers this gene has become mutated and no longer functional. Assays that detect such mutations are under development as prognostic indicators and to provide better guidance for treatment of these tumors. In addition, vaccine, gene therapy, and small molecule approaches which target P53 are all under active evaluation. While approaches based on P53 will not apply to all patients, this gene represents an attractive new target that could be applied across a large number of different types of cancer.
Registration :
Cambridge Healthtech Institute
1037 Chestnut Street
Newton Upper Falls, MA 02164 USA
tel: 617-630-1300
fax: 617-630-1325
Deadline for Abstracts: 9/95
Email for Requests and Registration: chi@healthtech.com